ライフサイエンスコーパス: probiotics

1 sly promoting growth of beneficial bacteria (probiotics).

2 ce and severity of adverse events related to probiotics.

3 can be reversed by favorable alterations by probiotics.

4 trategies for their prevention is the use of probiotics.

5 w, most research has focused on lactobacilli probiotics.

6 en systems, which include bioremediation and probiotics.

7 olated from each patient originated from the probiotics.

8 n a variety of commercial products including probiotics.

9 es infantis bacteremia in newborns receiving probiotics.

10 modulators, and recent use of antibiotics or probiotics.

11 ource for patients seeking information about probiotics.

12 risk for adverse events among patients given probiotics.

13 o adverse effects were related to the use of probiotics.

14 e against this pathogen, represent potential probiotics.

15 laiming various health benefits by acting as probiotics.

16 Lactic acid bacteria (LAB) are the common probiotics.

17 phenols, carotenoids, vitamins, enzymes, and probiotics.

18 microbiome and a brief review of the use of probiotics.

19 delivery carrier for oral administration of probiotics.

20 at-killed LAB may be developed as anti-virus probiotics.

21 nfections related to lactobacilli containing probiotics.

22 ential application for improving efficacy of probiotics.

23 ion in animals, targeted antibiotics, and/or probiotics.

24 management strategies, including the use of probiotics.

25 operationally referred to as next-generation probiotics, a concept that overlaps with the emerging co

26 dobacterium genus, which is commonly used in probiotics, accumulated in the ankylosing spondylitis pa

27 proaches have been recently studied; whether probiotics act by altering microbial communities or by m

28 ts of herbs (such as cannabis and curcumin), probiotics, acupuncture, exercise, and mind-body therapy

29 Prevention regimen with specific probiotics administered to the pregnant and breast-feedi

30 orted for probiotic encapsulation to protect probiotics against GI tract insults and improve their ad

31 creted to improve the protective activity of probiotics against Salmonella pathogenesis in C. elegans

32 nswers for presumed "fat drugs" and slimming probiotics alike.

33 Specific probiotics also have immunomodulatory and metabolic effe

34 Studies have shown that probiotics alter gut flora and lead to elaboration of fl

35 Preadministration and coadministration of probiotics ameliorated C. rodentium-induced barrier dysf

36 Additionally, microbiota perturbations by probiotics and antibiotics exert modulatory effects on s

37 Treatment including antivirals, probiotics and antibiotics helps to improve the microbio

38 ndomized controlled trials evaluating use of probiotics and CDI in hospitalized adults taking antibio

39 These ternary blends protected the probiotics and enhanced their resistance to simulated ga

40 on including, for example, administration of probiotics and fecal microbiota transplantation.

41 Predictors of response to lactulose, probiotics and L-ornithine-L-aspartate therapy in minima

42 spite evidence for the beneficial effects of probiotics and low-fat dairy products, to our knowledge,

43 that patients are likely interested in using probiotics and may have unrealistic expectations for the

44 Probiotics and omega-3 fatty acids may ameliorate diseas

45 ." We review some of the mechanisms by which probiotics and other beneficial commensals provide colon

46 Novel probiotics and prebiotics designed to manipulate the gut

47 Previous studies have suggested roles of probiotics and prebiotics on body weight management and

48 finition of psychobiotics be expanded beyond probiotics and prebiotics to include other means of infl

49 regulations governing introduction of novel probiotics and prebiotics vary by geographical region.

50 administration of synbiotics (combination of probiotics and prebiotics) and must have included an ass

51 ed MEDLINE, EMBASE, International Journal of Probiotics and Prebiotics, and The Cochrane Library data

52 addressed in any safety assessment of novel probiotics and prebiotics.

53 nt data suggest that the use of prophylactic probiotics and subglottic endotracheal tubes are cost-ef

54 , mucosal immunology, the health benefits of probiotics and the role of the microbiota during infecti

55 ological treatments, antidepressants, fiber, probiotics, and anticholinergics have not been adequatel

56 s of disease prevention, including vaccines, probiotics, and bacteriophages.

57 Predictors of response to lactulose, probiotics, and L-ornithine-L-aspartate therapy in minim

58 ted SIV-infected pigtail macaques with ARVs, probiotics, and prebiotics or with ARVs alone.

59 itions through administration of prebiotics, probiotics, and synbiotics.

60 luded subglottic suction endotracheal tubes, probiotics, and the Institute for Healthcare Improvement

61 The most advanced approaches are antibodies, probiotics, and vaccines in phase 2 and phase 3 trials.

62 s, targeting of gut microbiota by innovative probiotics, antibiotics, and fecal transplant, in combin

63 Probiotics appear to reduce infectious complications inc

64 Probiotics are able to cause this effect within the body

65 The pooled evidence suggests that probiotics are associated with a reduction in AAD.

66 ine: Moderate-quality evidence suggests that probiotics are associated with lower rates of antibiotic

67 More research is needed to determine which probiotics are associated with the greatest efficacy and

68 Probiotics are considered to be well tolerated, although

69 addition, the uses or indications for these probiotics are described, along with the types of clinic

70 To examine whether probiotics are effective in the prevention/management of

71 the incidence of resistance to antibiotics, probiotics are emerging as a promising adjunctive period

72 Probiotics are extensively used to promote gastrointesti

73 itro studies all support the assumption that probiotics are generally safe for most populations.

74 targets, and LTA mutant strains as improved probiotics are highlighted.

75 Probiotics are known to improve gut maturity and functio

76 Probiotics are live bacteria that colonize the gastroint

77 Probiotics are live microorganisms intended to confer a

78 Probiotics are living microorganisms that provide benefi

79 Moreover, our results indicate that probiotics are of potential therapeutic utility to count

80 ent meta-analyses have called for the use of probiotics as preventive therapy in subsets of this popu

81 we provide data supporting the candidacy of probiotics as such a therapeutic modality against obesit

82 and modulation of the gut microbiota (e.g., probiotics) as a potential treatment to decrease parasit

83 e supplemented with vitamin D and additional probiotics associated with positive health outcomes.

84 ntial wall material for targeted delivery of probiotics by altering its digestion.

85 Little is known about whether probiotics can affect outcomes of patients with cirrhosi

86 Probiotics can alleviate diarrhea in children and enhanc

87 Whether probiotics can be used to interrupt the infectious proce

88 In patients without prior OHE, probiotics can be useful in preventing OHE.

89 , this represents a novel mechanism by which probiotics can locally dampen innate immune responses an

90 Probiotics can modulate the immune system in healthy ind

91 This study provides evidence that probiotics can prevent illness and treat disease in an a

92 Probiotics can reduce adverse effects and improve the in

93 BACKGROUND & AIMS: Probiotics can reduce symptoms of irritable bowel syndro

94 is, we found evidence that administration of probiotics closer to the first dose of antibiotic reduce

95 lling critically ill adults, which evaluated probiotics compared to a placebo and reported clinically

96 Not only are probiotics considered beneficial to digestive health, bu

97 Probiotics contained Lactobacillus acidophillus, Lactoba

98 nd bacteremia from lactobacillus after using probiotics containing lactobacilli in the course of her

99 fect is warranted with the increasing use of probiotics containing lactobacilli.

100 Supplementation with probiotics could be a potential strategy to reduce gastr

101 nate respiration or treatment using targeted probiotics could prevent microbiota alterations and infl

102 Its enrichment with probiotics could thus further enhance its functional pro

103 cies and functions, for example, by pre- and probiotics, could enhance microbiome resilience and lead

104 w generation of antibiotics, prebiotics, and probiotics coupled with novel, systems biology-driven di

105 The leading probiotics currently available to consumers are generall

106 ro treatment of mononuclear cells with these probiotics demonstrated that EcN, but not LGG, induced I

107 However, how probiotics do this remains unclear.

108 ized controlled trials evaluating the use of probiotics during pregnancy or early infancy for prevent

109 Three of the 5 management trials concluded probiotics effectively treat colic in breastfed babies;

110 Probiotics encapsulated with the ternary blends incorpor

111 These probiotics enhanced the generation of bioactive peptides

112 Although probiotics exert beneficial effects on gut homeostasis,

113 ptoms, although the mechanisms through which probiotics exert their beneficial effects are largely un

114 e been learned from working with traditional probiotics, explore the kinds of organisms that are like

115 iometabolic effects of phenolics, dairy fat, probiotics, fermentation, coffee, tea, cocoa, eggs, spec

116 e balance of intestinal flora by introducing probiotics for disease prevention and treatment could be

117 evidence to support the use of prebiotics or probiotics for food allergy prevention.

118 Their use as probiotics for prevention of Clostridium difficile infec

119 y data suggest a small, beneficial effect of probiotics for the prevention of common cold illness.

120 tudy highlight the potential for repurposing probiotics for the therapy of osteoporosis.

121 h multiple studies have evaluated the use of probiotics for this indication in preterm infants, these

122 for alternatives to pharmaceuticals, such as probiotics, for the prevention of allergic disease.

123 rleukin 17 transcription was suppressed with probiotics given up to 3 days after infection.

124 y of delay in starting probiotics (P = .04); probiotics given within 2 days of antibiotic initiation

125 (95% CI 0.68-1.27); 73 (11%) infants in the probiotics group had sepsis compared with 77 (12%) in th

126 -obesity group and lyophilized monocomponent probiotics groups (III-V).

127 roup II, MSG-obesity group) and treated with probiotics (groups III-VII).

128 Infants treated with probiotics had a significantly lower RR for eczema compa

129 Probiotics had no effect on intensive care unit or hospi

130 Probiotics had no effect on the risk of atopic sensitiza

131 The consumption of probiotics has become increasingly popular as a means to

132 he intestinal microbiota with antibiotics or probiotics has not been shown to produce these changes i

133 ptide liberation by lactic acid bacteria and probiotics has received a great focus.

134 Probiotics have a possible role in the treatment of pedi

135 Probiotics have become one of effective alternatives to

136 One condition for which probiotics have been advocated is the diarrhea that is a

137 The beneficial effects of probiotics have been demonstrated in many diseases.

138 Probiotics have been hypothesized to affect immunologic

139 Probiotics have been increasingly investigated in its ma

140 Therefore, probiotics have been suggested as a potential treatment

141 Given this scenario, probiotics have been suggested as a useful alternative f

142 Probiotics have been used safely for years.

143 Clearly, some probiotics have considerable potential in the management

144 Supplements such as probiotics have not proved helpful, but allergen-specifi

145 Probiotics have shown beneficial effects on health and p

146 Probiotics have shown promising potential in reducing th

147 Although probiotics have shown success in preventing the developm

148 IGNIFICANCE STATEMENT Commercially available probiotics have the potential to modify visceral pain.

149 , easy answers (whether about antibiotics or probiotics) have again given way to an appreciation for

150 Live bacteria (such as probiotics) have long been used to modulate gut microbio

151 us antibiotic alternatives, such as pre- and probiotics, have been proposed but show variable success

152 Synbiotics, a mixture of prebiotics and probiotics, have been used for the prevention and treatm

153 Developing genetically engineered probiotics holds great promise as a new therapeutic para

154 vidence suggests functional foods containing probiotics improve gastrointestinal transit, however, da

155 Probiotics improved stool consistency (SMD: +0.55; 95% C

156 RCTs that reported administration of probiotics in adults with functional constipation were i

157 alyzed the available data on the efficacy of probiotics in candidal colonization of host surfaces.

158 tematic review was to evaluate the effect of probiotics in critically ill patients on clinical outcom

159 review recent regulatory aspects related to probiotics in food.

160 High-quality trials of probiotics in gastrointestinal disorders as well as labo

161 ies regarding the biological consequences of probiotics in host immunity suggested that they regulate

162 m studies demonstrating the effectiveness of probiotics in IBS, although recommendations should be ma

163 tive therapies, particularly ondansetron and probiotics in improving AGE outcomes.

164 quipped to answer questions on the safety of probiotics in intervention studies with confidence." Cri

165 e insufficient to support the routine use of probiotics in outpatient pediatric AGE.

166 ed to definitively guide the clinical use of probiotics in outpatients in developed countries.

167 There is growing interest in the use of probiotics in periodontal therapy; however, until now, m

168 trials have shown the benefits of a range of probiotics in pouchitis and in ulcerative colitis, altho

169 The aim of the Probiotics in Pregnancy Study was to investigate the eff

170 s have provided evidence for the efficacy of probiotics in preventing Clostridium difficile infection

171 Long-term effects of probiotics in primary prevention of allergic disease nee

172 required to establish safety and efficacy of probiotics in reducing fracture risk in people.

173 ls have also shown the beneficial effects of probiotics in reducing oral, vaginal, and enteric coloni

174 ion to identify characteristics of effective probiotics in relation to their interactions with Bd, th

175 The efficacy of probiotics in the context of atopic diseases has been we

176 Further research on probiotics in the critically ill is warranted.

177 ectious diseases and for stably establishing probiotics in the gut.

178 ence for the mechanisms and effectiveness of probiotics in the management of these disorders.

179 The growth of probiotics in the presence of total, acidic or neutral p

180 Registered title: Probiotics in the prevention of atopy in infants and chi

181 the evidence does support a future role for probiotics in the prevention of NEC, it is of utmost imp

182 erance in pregnancy, but glycemic effects of probiotics in this specific obstetric group require addi

183 idial gastroenteritis emphasizes the role of probiotics in treating intestinal impairment after infec

184 te to significantly enhanced survival of LbL-probiotics in vivo.

185 dies are required to assess the viability of probiotics in yogurts protected using MTGase-mediated mi

186 The formulation of these probiotics into microcapsules is an emerging method to r

187 where the rational design of next-generation probiotics is being actively pursued to prevent disease

188 known, but the role of Lactobacillus species probiotics is still controversial.

189 However, a concern for application of probiotics is the loss of viability during storage and g

190 ry fiber may be of value, but the utility of probiotics is, as yet, unclear.

191 s abundant in calcium, zinc, B vitamins, and probiotics; it is a good source of protein; and it may b

192 Lactulose, probiotics, L-ornithine-L-aspartate, and potassium-iron-

193 tment of sex steroid-deficient mice with the probiotics Lactobacillus rhamnosus GG (LGG) or the comme

194 RV (HRV) in gnotobiotic pigs colonized with probiotics (Lactobacillus rhamnosus strain GG [LGG] and

195 allel randomized controlled trials (RCTs) of probiotics (Lactobacillus, Bifidobacterium, Saccharomyce

196 Two candidate probiotics, Lactococcus lactis NCC 2287 and Bifidobacter

197 Thus, probiotics LGG+Bb12 exert divergent immunomodulating eff

198 This indicates that probiotics may also release antifungal compounds in thei

199 Probiotics may be a promising solution.

200 Probiotics may be effective through their impact on the

201 se findings broaden our understanding of how probiotics may beneficially affect brain function in the

202 These data suggest that the use of probiotics may have promise for the prevention of common

203 nd human studies suggest that prebiotics and probiotics may have therapeutic roles in maintaining a m

204 Probiotics may help improve natural immunity in patients

205 Ondansetron and probiotics may improve patient outcomes in pediatric AGE

206 Probiotics may improve quality of life during allergy se

207 Probiotics may improve whole gut transit time, stool fre

208 Probiotics may prevent intestinal inflammatory diseases

209 The use of heat-killed probiotics may provide therapeutic benefit while minimiz

210 Thus probiotics may provide therapeutic strategies for neurod

211 Probiotics may reduce necrotising enterocolitis and late

212 Probiotics may serve in the future as a worthy ally in t

213 ions highlight a novel pathway through which probiotics mediate cerebral changes and alter behavior.

214 ta modification with specific prebiotics and probiotics might offer a novel and cost-effective means

215 Interactions between probiotics, nutritional components and the intestinal ba

216 hat Lactobacillus fermentum, one of the main probiotics of the microbiota, exhibits an extraordinary

217 The study suggests that probiotics offer promise as a potential therapy for the

218 ry, the mechanisms underlying the effects of probiotics on aging have rarely been assessed.

219 We assessed the evidence on effects of probiotics on enteral nutrition in preterm neonates.

220 The aim was to investigate the effect of probiotics on gut transit time, stool output, and consti

221 e is known about the impact of commonly used probiotics on human RV (HRV) infection.

222 studies have reported beneficial effects of probiotics on maternal glycemia in healthy pregnant wome

223 inhibitory effect of some commercial dietary probiotics on periodontopathogens, comparing this inhibi

224 ecent studies report a significant effect of probiotics on the occurrence of common cold illnesses in

225 ts received one sachet twice a day of either probiotics or placebo for 7 days.

226 ii) Mothers interested in probiotics or research or reporting infants' adverse eve

227 either RCE (60 mg isoflavone aglycones/d and probiotics) or a masked placebo [control (CON)].RCE sign

228 toms after its manipulation with prebiotics, probiotics, or antibiotics.

229 efficacy for every day of delay in starting probiotics (P = .04); probiotics given within 2 days of

230 nsumed raw food (P = 0.01), to have consumed probiotics (P = 0.002), or to have been given antibiotic

231 ber of well-controlled studies indicate that probiotics, particularly lactobacilli, suppressCandidagr

232 strointestinal (GI) tract through the use of probiotics (PBio) is a safe and well-tolerated approach

233 f strategies, such as targeted therapeutics, probiotics, prebiotics and synbiotics, to prevent pertur

234 uman-host targets that improve upon existing probiotics, prebiotics or antibiotics.

235 re, microbiota management models for testing probiotics, prebiotics, and synbiotics have been develop

236 Recently, the effectiveness of probiotics, prebiotics, and synbiotics in reducing posto

237 formula with additional active ingredients (probiotics, prebiotics, or both) (LPFA) and breastfed in

238 lows for a more holistic approach when using probiotics, prebiotics, synbiotics, antibiotics, and ant

239 Probiotics prevent disease induced by Citrobacter rodent

240 nonantibiotic prophylactic measures such as probiotics, prokinetics, bile acids, statins, and hemato

241 Probiotics promoted transcription of interleukin 10 and

242 trials (1825 infants) reviewed, 6 suggested probiotics reduced crying, and 6 did not.

243 Probiotics reduced the incidence of CDAD by 66% (pooled

244 Probiotics reduced the time to full enteral feeds in pre

245 Although probiotics remain a promising option, there are challeng

246 Additionally and not unexpectedly, probiotics reversed hypogonadal osteopenia in sex steroi

247 a rates were also significantly reduced with probiotics (risk ratio 0.75; 95% confidence interval 0.5

248 ecially those supplemented with a mixture of probiotics (RR 0.54 [95% CI: 0.43-0.68], P < 0.00001).

249 [RR], 0.24; 95% CI, 0.12-0.49; P < .001) or probiotics (RR, 0.50; 95% CI, 0.28-0.90; P = .022) compa

250 Prophylactic agents such as probiotics should be studied prospectively in patients w

251 Beneficial microbes and probiotics show promise for the treatment of pediatric g

252 Thus, probiotics showed therapeutic potential for diseases, in

253 Overall, probiotics significantly reduced whole gut transit time

254 These findings suggest that probiotics such as VSL#3 can modulate the gut microbiota

255 et (eg, dietary fiber, oligosaccharides, and probiotics) suggest that an individual's dietary folate

256 The best evidence lies with probiotics supplementation in mothers and infants in pre

257 Microencapsulated probiotics survived well in simulated gastrointestinal c

258 es or strains, doses, and duration of use of probiotics that are most efficacious.

259 Our data further suggest that probiotics that decrease gut permeability have potential

260 egies and filtering protocols that result in probiotics that inhibit Bd under ecologically relevant c

261 nd suggests novel metabolic targets for pre-/probiotics therapies.

262 nto the mechanisms adopted by commensals and probiotics to adapt to the mucosal environment.

263 e composition and highlight the potential of probiotics to attenuate high-fat diet-related metabolic

264 d prescribing prophylactic vancomycin and/or probiotics to colonized patients to prevent progression

265 tract (RCE) rich in isoflavone aglycones and probiotics to concomitantly promote uptake and a favorab

266 Administration of probiotics to premature newborns has been shown to preve

267 n-pathogenic organisms and have been used as probiotics to prevent antibiotic associated diarrhea.

268 tors (variable); (3) utilization of specific probiotics to prevent C. difficile overgrowth (8/8); (4)

269 Long-term PPI users should not routinely use probiotics to prevent infection.

270 usses the literature available on the use of probiotics to prevent primary and secondary CDI.

271 is moderate evidence on the effectiveness of probiotics to prevent primary CDI, but there are few dat

272 f studies have investigated the potential of probiotics to promote wound healing in the digestive tra

273 The development of next-generation probiotics to reestablish colonization resistance and el

274 s that can be developed into next-generation probiotics to reestablish or enhance colonization resist

275 Our results indicate that development of probiotics to target multiple E. coli pathotypes will be

276 Research on the use of probiotics to treat a variety of intestinal and nonintes

277 g might aid the design of novel biologics or probiotics to treat inflammatory bowel disease.

278 inistering certain strains of live bacteria (probiotics) to critically ill patients may restore balan

279 dition to human milk, such as prebiotics and probiotics, to the management of high-risk infants.

280 s which either did or did not contain active probiotics twice daily and to complete a daily diary.

281 further studies before any recommendation of probiotics use is made.

282 t asthma, although the results of studies of probiotics used together with prebiotics have been overa

283 present work describes the encapsulation of probiotics using a by-product as wall material and a pro

284 and to clarify the relative contributions of probiotics versus OIT.

285 The combination of probiotics, vitamins, and biological agents with AIT is

286 ndomized infants 3 months or younger to oral probiotics vs placebo or no or standard treatment with t

287 Conversely, feeding SCI mice commercial probiotics (VSL#3) enriched with lactic acid-producing b

288 The treatment with probiotics was started at the age of 1 month.

289 adequate amounts and, as such, are labeled "probiotics." We review some of the mechanisms by which p

290 Probiotics were associated with a trend toward reduced i

291 Probiotics were associated with reduced infectious compl

292 Meta-regression analysis demonstrated that probiotics were significantly more effective if given cl

293 ncapsulation system to preserve viability of probiotics when they are administrated orally and apply

294 This research shows that probiotics, when eaten, can improve the abnormal behavio

295 This review briefly describes the history of probiotics, where probiotic strains were originally isol

296 cs were previously defined as live bacteria (probiotics) which, when ingested, confer mental health b

297 The development of probiotics, which are living bacteria or yeasts used to

298 Whether probiotics, which can influence the microbiome, prevent

299 al genes and specific compounds derived from probiotics, which mediate immunoregulatory effects.

300 nd it useful to initiate conversations about probiotics within the context of a comprehensive health